New combo therapy offers hope for hard-to-treat nose cancer
NCT ID NCT07277764
First seen Jan 11, 2026 · Last updated May 01, 2026 · Updated 20 times
Summary
This study tests a new treatment for people whose nasopharyngeal cancer has come back and cannot be removed with surgery. The treatment uses a special pattern of low and high dose radiation along with an immunotherapy drug (anti-PD-1) to shrink tumors while protecting healthy tissue. About 23 participants will receive this therapy and be followed for up to 3 years to see how well it works and what side effects occur.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NASOPHARYNGEAL CARCINOMA (NPC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Jiangxi Cancer Hospital
RECRUITINGNanchang, Jiangxi, 330029, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.